Polynucleotide (PDRN) Bio-Stimulation

Overview

Polynucleotide (PN) and polydeoxyribonucleotide (PDRN) biostimulation represents one of the most scientifically grounded approaches in regenerative aesthetics. Unlike hyaluronic acid fillers — which volumise through hydrophilic gel deposition — or neurotoxins, which transiently paralyse muscle activity, polynucleotides work through a fundamentally different mechanism: they activate cellular receptor pathways that upregulate the fibroblast's own collagen and elastin synthesis machinery, triggering genuine tissue regeneration from within.

The result is not a volumising or relaxing effect but an improvement in intrinsic skin quality: increased dermal thickness, improved hydration, finer surface texture, reduced fine rhytids, and visibly more resilient skin. This aligns directly with what patients in 2026 increasingly demand — not artificial alteration of their appearance, but restoration of the biological quality their skin has lost.

Mechanism of Action

Polynucleotides are highly purified fragments of DNA — long chains of deoxyribonucleotide monomers — extracted and processed from salmon (Oncorhynchus mykiss) sperm, which shares approximately 85% genomic sequence homology with human DNA. Salmon-derived PDRN underwent extensive safety and efficacy research in European wound-healing medicine before transitioning into aesthetic applications.

Adenosine A2A Receptor Activation

The primary mechanism is activation of the adenosine A2A receptor on fibroblasts and other tissue cells. Polynucleotides are metabolised extracellularly by phosphodiesterases, releasing adenosine fragments that bind A2A receptors. A2A receptor activation produces multiple downstream effects: upregulation of VEGF (vascular endothelial growth factor) promoting neovascularisation, reduced inflammatory cytokine signalling, and direct stimulation of fibroblast proliferation and extracellular matrix production.

PCNA Pathway Activation

Polynucleotides also interact with PCNA (proliferating cell nuclear antigen), a key regulator of the DNA replication and repair cycle. PCNA binding promotes cell cycle progression in fibroblasts — accelerating the rate of new collagen- and elastin-producing cell generation. This "cell turnover acceleration" effect is distinct from the A2A receptor pathway and additive to it.

Antioxidant and Anti-Inflammatory Activity

Clinical and in-vitro research demonstrates that polynucleotides scavenge reactive oxygen species (ROS) and modulate the inflammatory cascade in treated tissues — reducing the chronic low-grade inflammation ("inflammaging") that drives dermal degradation in aged skin. This anti-inflammatory property also makes PDRN a useful adjunct treatment following laser resurfacing, microneedling, or other procedures that create controlled inflammatory responses.

Clinical Applications

• Facial skin quality restoration: Generalised improvement in dermal thickness, hydration, and fine rhytids — the most common indication.
• Periorbital rejuvenation: Improvement of the crepey skin quality characteristic of lower eyelid and lateral canthal aging. One of the few biostimulatory options safe for periorbital use.
• Neck and décolleté: The neck and chest are regions of particularly pronounced skin thinning with age; polynucleotides are well-tolerated in these anatomical zones.
• Post-procedure recovery augmentation: Used as an adjunct following laser resurfacing or microneedling to accelerate healing and amplify collagen induction.
• Scalp and hair: PDRN injections to the scalp are studied in androgenetic alopecia, producing improvements in hair follicle vascularity and follicular cell turnover.

Treatment Protocol

The standard initial series involves 3–4 treatment sessions spaced 2–4 weeks apart. Each session involves multiple intradermal or subdermal injections distributed across the treatment area using a fine 30–32 gauge needle or micro-cannula. Product volumes per session typically range from 2–4 mL for a full facial treatment. Sessions take 20–40 minutes.

First visible improvement is typically observed 4–6 weeks after the initial session as new collagen synthesis becomes measurable. Results continue to develop over the course of the series. Maintenance treatments at 3–6 month intervals are required to sustain results. Cumulative benefit over multiple treatment cycles has been demonstrated in cohort studies, with baseline dermal quality improving progressively across years of maintenance treatment.

Cost in the United States

The polynucleotide aesthetic market in the US is substantially less mature than in Europe and East Asia, where PDRN and PN products (Rejuran, PDRN Skin, Placentex Integro) have been used in mainstream aesthetic practice for over a decade. US practitioners offering these treatments work with imported formulations or with products recently entering the US market. A full initial series (3–4 sessions) ranges from $800–$3,000 depending on the product used, anatomical area treated, and practice pricing. Individual sessions range from $300–$900.

Risks and Contraindications

• Fish allergy: Polynucleotides are salmon-derived. Known salmon or fish allergy is an absolute contraindication. Allergy screening is mandatory before the first treatment.
• Injection-site reactions: Transient papules, erythema, and bruising at injection points — resolving within 24–48 hours. Minor swelling is expected.
• Active skin infection: Treatment must not proceed over infected skin.
• Pregnancy and breastfeeding: Safety data are insufficient; not recommended.

Polynucleotides are not volumising agents and cannot replace soft tissue filler where structural volume correction is the primary goal. They are correctly deployed when skin quality — not volume — is the target outcome.